Literature DB >> 8331231

MRI of primary lymphoma of the liver.

T Fukuya1, H Honda, S Murata, K Yasumori, T Hayashi, H Ishibashi, T Matsumata, K Masuda.   

Abstract

OBJECTIVE: The MR findings in two cases of primary lymphoma of the liver (PLL) are presented.
MATERIALS AND METHODS: MR of two cases of primary lymphoma of the liver were reviewed and its features were estimated.
RESULTS: Both cases showed a solitary large liver mass. On T1-weighted imaging the tumor was isointense in one and homogeneously hypointense to the liver parenchyma in the other. On T2-weighted imaging both tumors were homogeneously hyperintense. In one case the margin of the tumor was poorly defined, and portal branches were identified within the tumor, an unusual finding in other liver neoplasms.
CONCLUSION: In patients with liver masses with homogeneous intensity on MR but without liver dysfunction and other malignancies, PLL should be included in the differential diagnosis.

Entities:  

Mesh:

Year:  1993        PMID: 8331231     DOI: 10.1097/00004728-199307000-00014

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  3 in total

1.  Radiologically identifiable intratumoral portal vein in intrahepatic cholangiomas: a diagnostic pitfall.

Authors:  K Kaneko; H Honda; K Kajiyama; Y Yokomizo; N Hashiguchi; T Fukuya; Y Tateshi; T Ro; K Masuda
Journal:  Abdom Imaging       Date:  1996 Sep-Oct

2.  Primary malignant lymphoma in the porta hepatis: a case report.

Authors:  H Irie; H Honda; K Kaneko; T Kuroiwa; T Fukuya; K Yoshimitsu; H Aibe; K Masuda
Journal:  Abdom Imaging       Date:  1996 Sep-Oct

3.  A case of contiguous primary hepatic marginal zone B-cell lymphoma and hemangioma ultimately diagnosed using contrast-enhanced ultrasonography.

Authors:  Kazue Shiozawa; Manabu Watanabe; Takashi Ikehara; Yasushi Matsukiyo; Yoshinori Kikuchi; Hironori Kaneko; Yoichiro Okubo; Kazutoshi Shibuya; Yoshinori Igarashi; Yasukiyo Sumino
Journal:  Case Rep Oncol       Date:  2015-02-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.